a nuvista pharma initiative

medevista

Low concentration, micronized lotion of Halobetasol- A potent steroid balancing the efficacy & safety

HaloTop®
Halobetasol Propionate 0.01% Lotion

Drug Review

About psoriasis[1]

- Psoriasis is a chronic proliferative and inflammatory condition of the skin.
- It is characterized by erythematous plaques covered with silvery scales, particularly over the extensor surfaces, scalp, and lumbosacral region.
- Psoriasis affects populations worldwide, with prevalence ranging from 0.2% to 4.8%.

Gap analysis and unmet needs in halobetasol propionate (HP) lotion 0.01

- HP cream 0.05% is effective in psoriasis but may cause epidermal atrophy, irritation, hypopigmentation and is unsuitable for long-term (≤2 weeks) use due to HPA axis suppression.[2]
- High steroid load (0.05%) increases systemic absorption risk.[2]
- Cream formulation is greasy and less patient-friendly, leading to poor adherence in chronic dermatologic conditions.[2]
- Halobetasol lotion contains 0.01% halobetasol and reduced systemic absorption results in minimal suppression of HPA axis.
- HP lotion 0.01% provides enhanced percutaneous absorption, uniform skin distribution, and once-daily application, improving adherence and tolerability.[3]

HaloTop (halobetasol propionate lotion 0.01): Mechanism of action[4]

- HP is a potent corticosteroid that works by inhibiting the release of inflammatory mediators.
- Halobetasol, with its micronized and low-concentration formulation, ensures better skin penetration & retention, leading to enhanced efficacy at a lower dose.

Halobetasol propionate
↓
Binds to glucocorticoid receptor
↓
Modulates transcription of target genes
↓
Recreased inflammation, immune response & cell proliferation

HP lotion 0.01% gives better skin penetration than HP cream 0.05[4]



Treatment success (≥2-grade improvement in baseline investigator global assessment score & a score of clear or almost clear)[4]



Proven results[4]

- A novel HP lotion 0.01% uses a polymerized matrix with moisturizing oil droplets, enhancing skin hydration and forming a protective barrier.
- The lotion allows faster epidermal penetration with greater retention than HP cream 0.05%, while limiting dermal absorption.
- Clinical studies show HP lotion 0.01% is as effective as HP cream 0.05% in 2 weeks, despite one-fifth the concentration.
- Non-greasy, fast absorbing lotion for superior patient comfort.
- HP lotion 0.01% is well tolerated over 8 weeks of daily use, suggesting potential for longer-term management of moderate to severe psoriasis.

Low concentration, micronized lotion of Halobetasol-a potent steroid balancing the efficacy & safety

HaloTop®

Halobetasol Propionate 0.01% Lotion

Tough to the Disease, Gentle on the Skin

5X lower concentration steroid with enhanced skin penetration & retention

Less penetration into the deeper layer reduces steroid related systemic side effects

Non-greasy, Fast absorbing lotion for superior patient comfort

Suitable for long term use upto 8 weeks with an off treatment pause of 4 weeks

Rx HaloTop®

In steroid responsive skin condition

- Plaque Psoriasis (in adults and children ≥12 years)
- Atopic dermatitis
- Contact dermatitis

Dosage Guideline

Apply HaloTop® (Halobetasol Propionate) 0.01% lotion gently to the affected area once daily for up to 8 weeks, followed by a 4-week off-treatment period

Ref.: 1. Nair PA, Badri T. Psoriasis. [Updated 2023 Apr 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.; **2.** www.accessdata.fda.gov/drugsatfda_docs/label/2018/210566s000lbl.pdf.; **3.** www.accessdata.fda.gov/drugsatfda_docs/label/2018/209355s000lbl.pdf.; **4.** Bagel J, Thibodeaux QG, Han G. Halobetasol propionate for the management of psoriasis. Cutis. 2020 Feb;105(2):92-96;E4.

Scan here for full prescribing information

nuvista
care. unconditional.

Nuvista Pharma PLC. (a subsidiary of **Beximco Pharma**)
Dhaka-1216, Bangladesh | www.nuvistapharma.com | nuvistapharma

HAL-DRV010126PYM